Gilead, Viking and Bio­haven de­tail promis­ing pre­clin­i­cal re­search in obe­si­ty and NASH

In a twist, pre­clin­i­cal re­search in meta­bol­ic dis­ease is peak­ing more in­vestor in­ter­est at the Amer­i­can Di­a­betes As­so­ci­a­tion’s an­nu­al meet­ing than in past years. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.